Applied DNA Biotherapeutics Subsidiary Reports LinearDNA Platform Development Milestone: First Successful Administration Of LinearDNA In Vivo Via Lipid Nanoparticles (LNP)
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA Platform Development Milestone: First Successful Administration Of LinearDNA In Vivo Via Lipid Nanoparticles (LNP)
Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, the Company's majority-owned biotherapeutics subsidiary, has for the first time successfully administered and expressed a linearDNA-LNP construct in mice via routine intramuscular (IM) injection without the concurrent use of electroporation (EP) that utilizes electrical pulses to deliver DNA to target cells. The Company believes that the removal of the concurrent use of EP during administration potentially increases the commercial viability of LinearDNA-based therapies.
基於聚合酶鏈式反應的DNA技術領域的領先供應商應用DNA科學公司(納斯達克股票代碼：APDN)(以下簡稱“公司”)今天宣佈，公司控股的生物治療子公司LineaRx首次成功地通過常規肌肉注射(IM)在小鼠體內注射並表達了線性DNA-LNP結構，而無需同時使用利用電脈衝將DNA輸送到靶細胞的電穿孔(EP)。該公司認為，在給藥期間取消同時使用EP可能會增加基於LinearDNA的療法的商業可行性。
